A multi-billion-dollar acquisition within the radiopharmaceutical space could be percolating as Lantheus Holding considers a buyout offer from Curium Pharma, Bloomberg
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
Three vaccine biotechs to be bought by Lilly for up to $3.8B
Lilly dives into vaccine research with 3 biotech buyouts
Eli Lilly spending $3.8 billion to buy vaccine makers
Innovaccer picks up CaduceusHealth to offer end-to-end revenue cycle management
Eli Lilly announces acquisition of 3 vaccine makers in $4 billion deal - UPI.com
Eli Lilly to buy three small vaccine developers
Merck & Co. and Kelun-Biotech's sac-TMT is on fire this week with details or first reports of three positive phase 3 trials. |…
Bristol Myers Squibb is the latest large pharma company to be making a major bet on artificial intelligence,
Bristol Myers Squibb and Hengrui Pharma signed a massive deal worth up to $15.2 billion. Takeda aims to cut 4,500 jobs in fiscal…
After striking radiopharmaceutical supply deals with pharma giants Novartis and AstraZeneca within the last six months, Niowave…
London-based Global Healthcare Opportunities and Singapore-based CBC Group announced plans to merge, creating what they called…
With phase 3 results that have “exceeded” BioMarin’s expectations, according to R&D chief Greg Friberg, M.D., the California…
